Table 4.

Recommendation percentages for Phase II experimentation under the six-parameter model and the average percentage of true MTDs selected by the design.

Toxicity (%)	Design
	D1 Ω1	D1 Ω2	D1 Ω3	D2 Ω1	D2 Ω2	D2 Ω3
Scenario 1: in agreement with prior
Far below TTL 0–14	1.4	0.7	0.5	0.7	1.0	0.5
Below TTL 15–24	19.6	17.4	16.0	21.0	19.9	20.1
TTL 25–34	58.4	58.5	61.4	60.0	58.3	60.2
Above TTL 35–44	20.7	23.2	22.1	18.2	20.8	19.2
Far above TTL ≥ 45	0.0	0.2	0.1	0.1	0.1	0.0
% of MTDs selected	16	18	17	22	21	23
Scenario 2: toxic
Far below TTL 0 - 14	1.0	1.0	0.6	1.3	1.6	1.4
Below TTL 15–24	25.1	19.6	21.8	24.5	23.2	24.6
TTL 25–34	47.2	55.5	51.8	49.6	51.9	53.1
Above TTL 35–44	23.5	21.9	23.3	21.7	21.1	19.0
Far above TTL ≥ 45	3.3	2.0	2.5	2.8	2.2	1.9
% of MTDs selected	18	21	18	27	24	25
Scenario 3: asymmetric toxic
Far below TTL 0–14	1.4	0.8	0.8	1.2	1.2	0.7
Below TTL 15–24	10.1	10.8	10.3	10.8	11.1	10.9
TTL 25–34	29.6	34.9	36.9	30.9	33.6	34.9
Above TTL 35–44	53.9	49.8	47.6	50.2	49.2	48.1
Far above TTL ≥ 45	4.9	3.7	4.5	6.9	4.8	5.5
% of MTDs selected	8	10	9	12	11	13
Scenario 4: flat
Far below TTL 0–14	0.0	0.0	0.0	0.0	0.0	0.0
Below TTL 15–24	13.7	12.3	11.9	14.0	11.7	11.6
TTL 25–34	73.1	75.4	70.8	76.2	75.7	74.8
Above TTL 35–44	13.1	12.3	17.3	9.8	12.6	13.6
Far above TTL ≥ 45	0.0	0.0	0.0	0.0	0.0	0.0
% of MTDs selected	7	7	6	9	8	8

TTL, target toxicity level. MTD, maximum tolerated dose.